Payer PolicyActive
CMM-204: Prolotherapy
EVICORE-MSK_ADVANCED-83A7B5B8
EviCore by Evernorth
Effective: August 11, 2017
Updated: January 13, 2026
created · Dec 5, 2025
Policy Summary
Prolotherapy (CPT M0076) is considered experimental, investigational, and unproven for treatment of musculoskeletal pain or instability and is therefore not covered. No specific documentation requirements or prior-authorization criteria are provided in the guideline.
Coverage Criteria Preview
Key requirements from the full policy
"Based on the lack of conclusive scientific evidence demonstrating the clinical efficacy of prolotherapy combined with the potential to expose individuals to serious adverse side effects or complica..."
Sign up to see full coverage criteria, indications, and limitations.